Nimer Alsaid

Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

BackgroundTreatments for metastatic pancreatic cancer include monotherapy with gemcitabine (GEM); combinations of GEM with oxaliplatin (OXu2009+u2009GEM), cisplatin (CISu2009+u2009GEM), capecitabine (CAPu2009+u2009GEM), or nab-paclitaxel (NAB-Pu2009+u2009GEM); and the non-GEM combination FOLFIRINOX. Combination therapies have yielded better survival outcomes than GEM alone. A sponsor-independent economic evaluation of these regimens has not been conducted for USA.ObjectiveThe objective of this study was to estimate the cost utility and cost effectiveness of these regimens from the payer perspective for USA.MethodsA three-state Markov model (progression-free, progressed disease, death) simulating the total costs and health outcomes (quality-adjusted life-years; life-years) was developed to estimate the incremental cost-utility and cost-effectiveness ratios. FOLFIRINOX clinical data were obtained from trial and indirect estimates were obtained from network meta-analyses. Lifetime horizon and 3%/year discount rates were used.ResultsFOLFIRINOX was the most expensive regimen and GEM the least costly regimen. Compared to GEM, all but one (CISu2009+u2009GEM) regimen were found to be more effective in quality-adjusted life-years and life-years. Compared to GEM, the incremental cost-utility ratios for CAPu2009+u2009GEM, OX-GEM, NAB-Pu2009+u2009GEM, and FOLFIRINOX, were US

Establishing the Validity and Reliability Evidence of Preceptor Assessment of Student Tool

180,503, US

Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).

197,993, US

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

204,833, and US

Risk of biochemical recurrence (BCR) in prostate cancer (PCa) patients (pts) with perineural invasion (PNI): Systematic review and meta-analysis.

265,718 per additional quality-adjusted life-year, respectively; and the incremental cost-effectiveness ratios were US

Comparative efficacy and safety of immunotherapies targeting PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: Bayesian network meta-analysis.

88,181, US

Progression-free(PFS) and overall survival (OS) in treatment of BRAF mutation-positive metastatic melanoma: Bayesian network meta-analysis.

87,620, US

An Algorithm To Quantttatively Estimate Extrapolated Lifetime Survival Curves For Economic Evaluation (EE) of Cancer Treatments When Only Aggregated Patient Data Are Available; With Application To Metastatic Pancreatic Cancer

135,683, and US

Classification of Causes of Hospitalization For Heart Failure Patients In Cost-Effectiveness and Cost-Utility Evaluations of Pharmacotherapeutic, Surgical, and Managed-Care Interventions: Systematic Review

167,040 per additional life-year, respectively. A probabilistic sensitivity analysis confirmed the base-case analysis.ConclusionsThis sponsor-independent economic evaluation for USA found that OXu2009+u2009GEM, CAPu2009+u2009GEM, FOLFIRINOX, and NAB-Pu2009+u2009GEM, but not CISu2009+u2009GEM, were more expensive but also more effective than GEM alone in terms of quality-adjusted life-years and life-years gained. The NAB-Pu2009+u2009GEM regimen appears to be the most cost effective in USA at a willingness-to-pay threshold of US

Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM).

200,000/quality-adjusted life-year.